Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared a post on LinkedIn:
“It was a pleasure to contribute with our Oslo cohort to the Gynecologic Cancer InterGroup (GCIG) Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP), together with Katharina Bischof.
In this study, we analyzed a subset of patients with platinum-sensitive recurrent ovarian cancer (PS-ROC) who demonstrated exceptional responses to maintenance PARP inhibitors.
Key findings included:
- Patients who discontinued PARP inhibitors for reasons other than disease progression did not appear to experience inferior outcomes compared with those who continued treatment.
- The risk of secondary malignancies and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) was very low.
Functional cure may be possible, and these findings challenge current recommendations for indefinite PARP inhibitor treatment in the recurrent setting.
Thank you to Lucy Haggstrom and Michael Friedlander for their leadership, and congratulations to all colleagues from the Gynecologic Cancer InterGroup (GCIG) who contributed to this important collaborative effort.”
Title: Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
Authors: Lucy Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, Anna Jaeger, Linn Woelber, Hannah Woopen, Madeline Rhind, Jean-Sébastien Frenel, Aanum Aanum, Katharina Bischof, Marta Mongillo, Allison L. Brodsky, Jonathan Ledermann, Talayeh S. Ghezelayagh, Ingrid Boere, Sabrina Kaiser, Constanza Maximiano, Ora Rosengarten, Tamar Safra, Ana Pertejo, Sabrina Cecere, Isabelle Ray-Coquard, Stephanie Lheureux, Ros Glasspool, Marta Gil-Martin, Laura Tookman, Se Ik Kim, Suzana Mittelstadt, Miguel Corbellas Aparicio, Isabel Palacio, Cristina Martin-Lorente, Rebecca Kristeleit, Helena de la Cueva,
Nelleke Ottevanger, Maria Quindós Varela, Hiroyuki Yoshida, Theresa Link, Lydia Gaba, Gloria Marquina, Nikki Burdett, Paul Johannet, Juliane Reichenbach, Tjoung-Won Park-Simon, Philip H. Klecker, Antonio González-Martín, Christian Marth, Clemens Liebrich, Levan Dzotsenidze, Sabine Heublein, Lawrence Kasherman, Cristina Perez, Maria Masvidal, Pau Guillén Sentís, Nikolaus de Gregorio, Franziska Hemptenmacher, Felix Hilpert, Jalid Sehouli, Clare Scott, Katherine Mary Tucker, Jack Dong, Cristina Fortuno, Amanda B. Spurdle, Michael Friedlander
Read The Full Article
Other articles featuring Kristina Lindemann on OncoDaily.